Aggressive Periodontitis
Conditions
Brief summary
The aim of the present study is to evaluate the clinical and microbiological efficacy of moxifloxacin or amoxicillin plus metronidazole in one-stage scaling and root planing in treating generalized aggressive periodontitis. Forty five subjects will be randomly allocated to 3 treatment groups. Subgingival plaque samples will be analysed for cultivable bacteria. The primary outcome variable to determine the superiority of one treatment over the others would be differences between groups for means CAL changes at 6 months post-treatment. Secondary outcome variables include differences between therapies for the mean changes in the mean levels of PD and the proportion of BOP.
Interventions
DRUGScaling and Root Planing combined with moxifloxacin
Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
Sponsors
Facultad Nacional de Salud Publica
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects ≤30 years of age * minimum of six permanent teeth, with at least one site each with probing depth (PD) and clinical attachment level (CAL) ≥5 mm and a minimum of six teeth other than first molars and incisors with at least one site each with PD and CAL ≥5 mm.
Exclusion criteria
* diabetes * cardiovascular diseases * immunological disorders or any other systemic disease that could alter the course of periodontal disease. * Pregnant or nursing women * smoking * allergy to amoxicillin, metronidazole, fluoroquinolones or moxifloxacin * consumption of systemic antimicrobials or anti-inflammatory drugs in the last 6 months * periodontal therapy during the last 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical attachment level | 3 and 6 months | It was defined that the primary outcome variable to determine the superiority of one treatment over the other would be differences between groups for means Clinical Attachment Level changes at 6 months post-treatment. This is a measure assessing change between two time points . |
Countries
Colombia
Outcome results
None listed